DUBLIN–(BUSINESS WIRE)–The “Artificial Intelligence-enabled Drug Discovery, 2022: Frost Radar Report” report has been added to ResearchAndMarkets.com’s offering.
Pharmaceutical drug discovery and development has been suffering from declining success rates with new molecules primarily because of poor external validity of preclinical models and lack of efficacy of the molecule in terms of the intended disease indication. Drug success rates continue to be in the range of only 1 in 10 that enters clinical phases pushing through to FDA approval.
Artificial intelligence (AI) is set to transform the drug discovery landscape. AI-based products and solutions are transforming drug discovery and development dynamics by enabling pharmaceutical players to shorten discovery timelines, enhance process agility, increase prediction accuracy on efficacy and safety, and improve the opportunity to diversify drug pipelines using a cost-effective model.
Most pharmaceutical vendors are focused on collecting, creating, and augmenting data from across laboratories, clinical trials, real-world evidence, biobanks, and repositories. The increasing volume and veracity of clinical and research data is compelling traditional providers to leverage enabling tools and technologies such as cloud computing, AI and machine learning, natural language processing, and advanced analytics to make a shift to a relatively fast, rational data-driven drug discovery and development approach.
To remain competitive, companies must strike the right balance of data, AI, and computational capability and match it with the wet lab capability. There remains inadequate understanding of the biological networks and drug-target interactions. Enter AI, which has been able to support the identification and prioritization of disease-specific therapeutic targets based on gene-disease associations. Such results must be replicated and validated through in vitro experiments and in vivo models.
Frost & Sullivan finds that the impact of AI on the entire pharma value chain can more than double what is achievable using traditional analytics and capture between 2% and 3% of industry revenue, amounting to more than $50 billion in potential annual impact.
Key Topics Covered:
1. Strategic Imperative and Growth Environment
- Strategic Imperative
- Growth Environment
2. Frost RadarT
- Frost RadarT: AI-enabled Drug Discovery
- Frost RadarT: Competitive Environment
3. Companies to Action
- AbCellera Biologics
- Atomwise
- BenevolentAI
- Berg Health
- Black Diamond Therapeutics
- Deep Genomics
- Evaxion Biotech
- Exscientia
- Generate Biomedicines
- GritstoneBio
- Healx
- Insilico Medicine
- Insitro
- Neumora Therapeutics
- Recursion
- Relay Therapeutics
- Schrodinger
- Valo Health
- XtalPi
4. Strategic Insights
5. Next Steps: Leveraging the Frost RadarT to Empower Key Stakeholders
- Significance of Being on the Frost RadarT
- Frost RadarT Empowers the CEO’s Growth Team
- Frost RadarT Empowers Investors
- Frost RadarT Empowers Customers
- Frost RadarT Empowers the Board of Directors
6. Frost RadarTAnalytics
- Frost RadarT: Benchmarking Future Growth Potential
Companies Mentioned
- AbCellera Biologics
- Atomwise
- BenevolentAI
- Berg Health
- Black Diamond Therapeutics
- Deep Genomics
- Evaxion Biotech
- Exscientia
- Generate Biomedicines
- GritstoneBio
- Healx
- Insilico Medicine
- Insitro
- Neumora Therapeutics
- Recursion
- Relay Therapeutics
- Schrodinger
- Valo Health
- XtalPi
For more information about this report visit https://www.researchandmarkets.com/r/nmkkbm
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900